AstraZeneca Plc (NASDAQ:AZN) on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when combined with lenvatinib and transarterial chemoembolization (TACE), significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma (a type of liver cancer) eligible for embolization.